Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat and Nivolumab for Cholangiocarcinoma and Pancreatic Cancer
NCT03250273Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2017
- Primary completion
- Nov 2020
- Countries
- 1
01
Overview
A Phase 2 trial of entinostat in cholangiocarcinoma (CCA), pancreatic adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Nov 2017; status: completed.
02
Drugs
entinostat
03
Conditions
cholangiocarcinoma (CCA)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03250273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03250273.